262 related articles for article (PubMed ID: 37602255)
1. FcRN receptor antagonists in the management of myasthenia gravis.
Bhandari V; Bril V
Front Neurol; 2023; 14():1229112. PubMed ID: 37602255
[TBL] [Abstract][Full Text] [Related]
2. FcRn inhibitors: a novel option for the treatment of myasthenia gravis.
Zhu LN; Hou HM; Wang S; Zhang S; Wang GG; Guo ZY; Wu J
Neural Regen Res; 2023 Aug; 18(8):1637-1644. PubMed ID: 36751773
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis.
Li J; Wu X; Chu T; Tan X; Wang S; Qu R; Chen Z; Wang Z
J Neurol; 2024 May; 271(5):2298-2308. PubMed ID: 38431900
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis.
Sivadasan A; Bril V
Immunotherapy; 2023 Jun; 15(8):553-563. PubMed ID: 37013835
[TBL] [Abstract][Full Text] [Related]
5. Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis.
Gable KL; Guptill JT
Front Immunol; 2019; 10():3052. PubMed ID: 31998320
[TBL] [Abstract][Full Text] [Related]
6. FcRn Inhibitor Therapies in Neurologic Diseases.
Alfaidi N; Karmastaji S; Matic A; Bril V
CNS Drugs; 2024 Jun; 38(6):425-441. PubMed ID: 38724842
[TBL] [Abstract][Full Text] [Related]
7. The importance of FcRn in neuro-immunotherapies: From IgG catabolism,
Dalakas MC; Spaeth PJ
Ther Adv Neurol Disord; 2021; 14():1756286421997381. PubMed ID: 33717213
[TBL] [Abstract][Full Text] [Related]
8. IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis.
Wolfe GI; Ward ES; de Haard H; Ulrichts P; Mozaffar T; Pasnoor M; Vidarsson G
J Neurol Sci; 2021 Nov; 430():118074. PubMed ID: 34563918
[TBL] [Abstract][Full Text] [Related]
9. [Neonatal Fc receptor (FcRn)-A Novel Therapeutic Approach for Autoimmune Disease].
Murai H; Harada D
Brain Nerve; 2024 Feb; 76(2):183-191. PubMed ID: 38351566
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.
Menon D; Bril V
Drugs; 2022 Jun; 82(8):865-887. PubMed ID: 35639288
[TBL] [Abstract][Full Text] [Related]
11. Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.
Di Stefano V; Alonge P; Rini N; Militello M; Lupica A; Torrente A; Brighina F
J Neurol; 2024 Jan; 271(1):254-262. PubMed ID: 37682316
[TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.
Smith B; Kiessling A; Lledo-Garcia R; Dixon KL; Christodoulou L; Catley MC; Atherfold P; D'Hooghe LE; Finney H; Greenslade K; Hailu H; Kevorkian L; Lightwood D; Meier C; Munro R; Qureshi O; Sarkar K; Shaw SP; Tewari R; Turner A; Tyson K; West S; Shaw S; Brennan FR
MAbs; 2018 Oct; 10(7):1111-1130. PubMed ID: 30130439
[TBL] [Abstract][Full Text] [Related]
13. Neonatal Fc Receptor Inhibitor Therapeutics in Neuromuscular Disease.
Jaffry M; Menkes DL; Shaikh A; Mandava K; Kothari O; Jaffry K; Souayah N
J Clin Neuromuscul Dis; 2023 Jun; 24(4):188-198. PubMed ID: 37219862
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies.
Briani C; Visentin A
Neurotherapeutics; 2022 Apr; 19(3):874-884. PubMed ID: 35349079
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis.
Matic A; Alfaidi N; Bril V
Expert Opin Biol Ther; 2023; 23(12):1163-1171. PubMed ID: 38099334
[TBL] [Abstract][Full Text] [Related]
17. Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis.
Guptill JT; Sleasman JW; Steeland S; Sips M; Gelinas D; de Haard H; Azar A; Winthrop KL
Autoimmunity; 2022 Dec; 55(8):620-631. PubMed ID: 36036539
[TBL] [Abstract][Full Text] [Related]
18. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
[TBL] [Abstract][Full Text] [Related]
19. Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial.
Yan C; Yue Y; Guan Y; Bu B; Ke Q; Duan R; Deng H; Xue Q; Jiang H; Xiao F; Yang H; Chang T; Zou Z; Li H; Tan S; Xiao H; Zhou H; Zhang H; Meng Q; Li W; Li W; Guo J; Zhang Y; Li Z; Tu J; Shi J; Li W; Lee M; Chen Y; Tao X; Zhao S; Li P; Zhao C;
JAMA Neurol; 2024 Mar; 81(4):336-45. PubMed ID: 38436998
[TBL] [Abstract][Full Text] [Related]
20. Efgartigimod as a novel FcRn inhibitor for autoimmune disease.
Yang Y; Shen Z; Shi F; Wang F; Wen N
Neurol Sci; 2024 Apr; ():. PubMed ID: 38644454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
